With FDA Clinical Hold Lifted, Idenix Hopes To Combine Its “Nuc” With A Protease Inhibitor For HCV
This article was originally published in The Pink Sheet Daily
Idenix’s IDX184 is the only unpartnered nucleoside polymerase inhibitor for hepatitis C in clinical development. With an FDA hold lifted, the company wants to make quick progress testing ‘184 in interferon-free regimens for HCV.
You may also be interested in...
The Phase I-ready compound joins alisporivir, a cyclophilin inhibitor licensed from Debiopharm in 2010, in Novartis’ rather slight portfolio of HCV candidates.
Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker